What is Leash Bio?
Leash Bio operates at the intersection of biotechnology and artificial intelligence, addressing the critical bottleneck in modern medicinal chemistry: the lack of structured, high-quality experimental data. While machine learning has catalyzed breakthroughs in various fields, the company posits that medicinal chemistry requires a foundational shift toward purpose-built, massive datasets. Leash Bio is actively constructing this infrastructure by integrating physical measurements with sophisticated ML models. This dual-pronged strategy allows the company to generalize insights across diverse protein targets, ultimately facilitating the discovery of novel medicines with unprecedented precision and efficiency.
How much funding has Leash Bio raised?
Leash Bio has raised a total of $9.3M across 1 funding round:
Angel/Seed
$9.3M
Angel/Seed (2024): $9.3M with participation from Top Harvest Capital, Mitsui & Co Global Investment, MFV Partners, SpringTide Ventures, and Metaplanet
Key Investors in Leash Bio
Top Harvest Capital
Top Harvest Capital is a venture capital firm that invests in early-stage AI startups within the technology and healthcare sectors, focusing on transformative technologies.
Mitsui & Co Global Investment
Mitsui & Co. Global Investment specializes in guiding innovative entrepreneurs by providing strategic guidance and financial support to help them reach the global stage.
MFV Partners
MFV Partners is an early-stage venture capital firm based in the San Francisco Bay area, specializing in deep tech investments that address significant global challenges.
What's next for Leash Bio?
With the support of its latest funding, Leash Bio is set to transition from its foundational phase into a period of rapid operational scaling. The company's strategic roadmap focuses on expanding its high-throughput screening capabilities and refining its proprietary ML algorithms to ensure they remain generalizable across a wider array of therapeutic targets. As the firm continues to build its data moat, it is expected to attract further interest from both pharmaceutical partners and additional venture capital entities looking to capitalize on the next generation of AI-enabled drug discovery. The focus remains on long-term value creation through the systematic elimination of experimental uncertainty in the drug development lifecycle.
See full Leash Bio company page
